Why does crowding matter when testing visual acuity in amblyopia?

Children with amblyopia may identify isolated optotypes more easily than optotypes presented with surrounding visual information. Appropriate crowding can help reduce the risk of overestimating visual acuity.

What does noninferior mean in a clinical trial?

A noninferiority trial tests whether a new treatment performs no worse than an established treatment by more than a prespecified acceptable margin. A finding of noninferiority does not mean the treatments produced identical results or that the new treatment was superior.

Do digital amblyopia treatments replace patching?

Digital therapeutics are one of several treatment options for amblyopia, but they do not automatically replace patching. Treatment choice depends on factors including the type and severity of amblyopia, age, refractive correction, previous treatment, adherence, and the eye care professional's clinical judgment.

Why is stereoacuity measured in amblyopia research?

Amblyopia can affect binocular vision as well as monocular visual acuity. Stereoacuity testing provides information about depth discrimination and binocular function, allowing researchers to evaluate whether treatment changes more than visual acuity alone.

New Clinical Trial Compares Binocular Digital Therapy With Patching for Childhood Amblyopia

by Good-Lite Co October 2, 2026

by Good-Lite Co Published on October 2, 2026Updated on October 27, 2026

Patching has been part of amblyopia treatment for generations. It is familiar, inexpensive, and supported by a substantial clinical evidence base, but it can also demand a great deal of consistency from children and families over weeks or months of treatment.

That challenge helps explain the continued interest in digital approaches to amblyopia care. A multinational randomized clinical trial published in 2026 compared an eye-tracking binocular home treatment with conventional patching in 197 children between 4 and under 9 years of age. The findings do not suggest that digital therapy should replace patching, but they do add useful evidence to a treatment landscape that is becoming more varied.

The study also raises a broader issue that matters well beyond one treatment platform. As new approaches are introduced, researchers still need dependable ways to determine whether vision is actually improving, and that makes standardized visual acuity and binocular vision measurement just as important as the treatment being studied.

A Different Approach to Amblyopia Treatment

Children in the trial had anisometropic, small-angle strabismic, or mixed-mechanism amblyopia and were enrolled across 15 academic and community sites in China, Israel, and the United States. Most participants had anisometropic amblyopia, and just over half had not previously received amblyopia treatment.

One group used CureSight, an eye-tracking binocular system that alters what each eye sees while a child watches video content. The system tracks the child's gaze and blurs the central portion of the image shown to the fellow eye while leaving the central image presented to the amblyopic eye unaffected. The comparison group followed a conventional patching regimen.

The binocular treatment was prescribed for 90 minutes per day, five days per week, while patching was prescribed for two hours per day, seven days per week. Both groups were followed for 16 weeks, with visual acuity and stereoacuity assessed at regular intervals by examiners who were masked to treatment assignment.

The main outcome was the change in distance visual acuity in the amblyopic eye. That gave researchers a consistent way to compare how each group responded over the course of treatment.

What the Results Actually Showed

Both groups improved during the 16-week study period. In the modified intent-to-treat analysis, the binocular treatment met the study's prespecified criteria for noninferiority compared with patching, meaning it was not shown to perform worse than patching by more than the margin the researchers had defined before the trial.

Among children included in the per-protocol analysis, which required at least 60 percent treatment completion along with other protocol criteria, the binocular group showed a 0.04 logMAR advantage over patching. That difference was statistically significant, but the investigators explicitly described its size as not clinically meaningful. This distinction matters because a difference that can be detected statistically is not automatically large enough to change clinical care.

Stereoacuity told a slightly different story. It improved within both treatment groups, but the difference in improvement between the binocular and patching groups was not statistically significant. The study therefore did not demonstrate a clear advantage for the binocular treatment in stereoacuity.

Adherence was high in both groups during the trial, with median adherence of 97 percent in the binocular group and 95 percent in the patching group. The researchers also cautioned that adherence in everyday care may not match adherence inside a structured clinical trial, where families receive study visits, monitoring, and additional support.

One Trial Does Not Settle the Patching Question

The new study adds useful evidence, but it sits within a much larger body of amblyopia research. A separate 2026 systematic review and meta-analysis examined nine randomized controlled trials involving 986 children and found no significant overall difference in visual acuity improvement between binocular gaming approaches and conventional patching.

The results differed according to study design and treatment duration. Some shorter studies produced more favorable findings for binocular approaches, while longer-duration studies tended to favor patching. The technologies evaluated across those studies were also not identical, which makes it difficult to treat all forms of digital therapy as one intervention.

That is why the new trial is interesting without being definitive. Digital therapeutics are increasingly part of the range of approaches being investigated and used in amblyopia care, but established treatments such as refractive correction, patching, and atropine remain important parts of management. The American Academy of Ophthalmology's Amblyopia Preferred Practice Pattern also reflects this broader treatment landscape by including digital therapeutics among the available treatment options.

Measuring Improvement Matters as Much as the Treatment

The trial's focus on visual acuity is particularly relevant because treatment studies depend on being able to measure small changes reliably. The investigators used the Amblyopia Treatment Study visual acuity testing protocol, a standardized pediatric research method based on HOTV optotypes with surrounding crowding.

Crowding is especially relevant in amblyopia because a child may identify an isolated symbol more easily than the same symbol presented with surrounding visual information. If the optotype presentation, crowding, test distance, scoring method, illumination, or testing conditions change between visits, the measured difference may reflect more than the treatment itself.

That makes standardization a fundamental part of clinical research. A treatment can only be compared reliably when the outcome is measured in a consistent way across participants, study visits, and research sites. The same principle applies to stereoacuity, which provides additional information about binocular function that cannot be captured by monocular visual acuity alone.

Good-Lite has explored this issue previously in LEA SYMBOLS® in Clinical Research: Why Standardized Pediatric Optotypes Matter. That article looks at how standardized pediatric optotypes can help support consistent outcome measurement in studies involving children and other patients who may not be suited to letter-based testing.

What This Means for Pediatric Eye Care

The most important takeaway is not that digital treatment has beaten patching, because that is not what the evidence shows. The more meaningful development is that amblyopia treatment research is becoming broader, with investigators studying new ways to deliver therapy while also looking closely at adherence, treatment burden, visual acuity, and binocular function.

The study's limitations are also important. Participants were between 4 and under 9 years old, 84 percent had anisometropic amblyopia, and follow-up ended at 16 weeks, so the findings tell us more about short-term outcomes in this specific population than about long-term performance across every form of amblyopia.

Several investigators also disclosed financial relationships with NovaSight, the manufacturer of CureSight. Those disclosures do not invalidate the study, but they provide relevant context and reinforce the value of independent replication and comparison with the wider evidence base.

What does remain consistent is the need for repeatable measurement. Whether researchers are evaluating patching, atropine, optical treatment, or a digital therapeutic, reliable visual acuity and binocular vision testing provide the foundation for determining whether a treatment is actually making a difference.

Good-Lite Clinical Research Solutions

As clinical research becomes more sophisticated, standardized vision testing becomes more important rather than less. Good-Lite works with clinical research teams by providing vision testing solutions that support repeatable assessment, standardized protocols, and consistent visual outcome measurement across study visits and research sites.

The Good-Lite clinical research range includes the ESV3000™ and ESC2000™ ETDRS illuminated systems, ETDRS Original Series and 2000 Series Sloan Letter charts, HOTV ETDRS charts, LEA SYMBOLS® and LEA NUMBERS® logMAR charts, Landolt C clinical trial charts, and low-contrast testing options. These solutions support applications such as BCVA assessment, logMAR testing, pediatric visual acuity testing, low-contrast visual acuity, and research protocols requiring different optotype formats.

For research teams planning single-site or multi-site vision studies, Good-Lite offers equipment and chart formats that can help support consistent testing procedures across locations and follow-up visits. The dedicated Clinical Research resource brings these solutions together for teams developing or supporting vision-testing protocols.